Accurate Discrimination of Barrett's Esophagus and Esophageal Adenocarcinoma Using a Quantitative Three-Tiered Algorithm and Multimarker Real-time Reverse Transcription-PCR

@article{Mitas2005AccurateDO,
  title={Accurate Discrimination of Barrett's Esophagus and Esophageal Adenocarcinoma Using a Quantitative Three-Tiered Algorithm and Multimarker Real-time Reverse Transcription-PCR},
  author={Michael Mitas and Jonas S. Almeida and Kaidi Mikhitarian and William E. Gillanders and David N. Lewin and Demetri D Spyropoulos and Loretta Hoover and Amanda R Graham and Tammy F. Glenn and Peter King and David J. Cole and Robert Holbrook Hawes and Carolyn E. Reed and Brenda J. Hoffman},
  journal={Clinical Cancer Research},
  year={2005},
  volume={11},
  pages={2205 - 2214}
}
Esophageal adenocarcinoma (EA) is increasing faster than any other cancer in the U.S. In this report, we first show that EA can be distinguished from normal esophagus (NE) and esophageal squamous cell carcinoma by plotting expression values for EpCam, TFF1, and SBEM in three-dimensional Euclidean space. For monitoring progression of Barrett's esophagus (BE) to EA, we developed a highly sensitive assay for limited quantities of tissue whereby 50 ng of RNA are first converted to cDNA using 16… 
View on AACR
clincancerres.aacrjournals.org
26 Citations
Background Citations
4
Methods Citations
5

Figures and Tables from this paper

26 Citations

Citation Type

Citation Type

Differential gene expression in normal esophagus and Barrett’s esophagus
TLDR
The data suggested an important role of CDX1 and CDX2 in the development of BE, and the IHC-confirmed gene list will lead to future studies on the molecular mechanism of BE.
Gene expression alterations in formalin-fixed, paraffin-embedded Barrett esophagus and esophageal adenocarcinoma tissues.
TLDR
This study's findings for many highly differentially expressed genes are very similar to those previously reported, suggesting that these genes should be tested further in longitudinal studies for their potential role as biomarkers of progression to more advanced Barrett disease.
Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma
TLDR
It is concluded that an ACF-induced increase in EpCAM expression reflects the selection of a CSC subpopulation that underlies tumor development and drug resistance in EAC.
Molecular basis of Barrett’s oesophagus and oesophageal adenocarcinoma
TLDR
The demonstration of a “birth cohort effect”, with higher incidence rates in younger cohorts, would support the idea that exposure to environmental factors in early life is an important determinant of risk.
Prognostic significance of EpCAM expression in human esophageal cancer.
TLDR
Tumor-specific EpCAM expression and release into the circulation may serve as effective immunotherapy in esophageal cancer patients and is independently associated with prognosis.
Identification of a DNA methylome signature of esophageal squamous cell carcinoma and potential epigenetic biomarkers
TLDR
This is the first study to address methylation changes in ESCC in a large set of genes and shows methylome analysis is shown as a sensitive and powerful tool to identify molecular players in ES CC.
The differential expression of SPARC in esophageal squamous cell carcinoma.
TLDR
Findings revealed that SPARC was up-regulated in ESCC and was closely associated with ESCC metastasis and new insights into nuclei location of SPARC are provided.
Discrimination of Normal and Esophageal Cancer Plasma Proteomes by MALDI-TOF Mass Spectrometry
TLDR
These data lay the foundation for the development of a clinically useful test for esophageal cancer based on statistical analysis of proteomic spectra of patient plasma samples, and will be validated by analysis of larger patient cohorts, development of cancer-specific classifiers, and assessment of racial origin imbalances.
Molecular changes in the progression of Barrett’s oesophagus
TLDR
The ASPECT trial in the UK aims to establish whether chemoprevention with aspirin and a proton pump inhibitor will reduce adenocarcinoma development and mortality in patients with Barrett’s oesophagus and validate biomarkers for progression and clinical response.
Detection of mammaglobin mRNA in peripheral blood is associated with high grade breast cancer: Interim results of a prospective cohort study
TLDR
This study suggests that molecular detection of circulating cancer cells in PBL detected by RT-PCR is associated with high tumor grade and specifically that overexpression of the mam gene in P BL may be a poor prognostic indicator.
...
1
2
3
...

References

SHOWING 1-10 OF 57 REFERENCES
A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus
TLDR
The results suggest that mRNA expression quantitation of a panel of genes can discriminate between premalignant and malignant Barrett's disease and logistic regression and LDAs can be used to further identify, from the complete panel, gene subsets with the power to make these diagnostic distinctions.
Multifocal heterogeneity in villin and Ep‐CAM expression in Barrett's esophagus
TLDR
Investigation of the potential of villin, a cytoskeletal protein, and Ep‐CAM, a glandular epithelial glycoprotein, to serve as markers for enterocytic differentiation in Barrett's esophagus at the molecular level shows that BE represents a complex epithelium with significant heterogeneity in antigen expression and ultrastructural morphologic features.
Differential SPARC mRNA expression in Barrett's oesophagus
TLDR
The findings suggest that the upregulation of SPARC mRNA expression is an early event in the development and progression of BE and EA, and that high SPARC expression may be a clinically useful biomarker for the detection of occult adenocarcinoma.
Controversies in Barrett's esophagus: management of high grade dysplasia.
  • P. Sharma
  • Medicine
    Seminars in gastrointestinal disease
  • 2001
TLDR
The risks and benefits associated with each approach of managing high grade dysplasia are reviewed, with the advent of local endoscopic therapy, reversal therapy is being studied in patients with HGD and may be validated for this major indication.
Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations.
TLDR
The prevalence of Barrett's adenocarcinomas expressing c-erbB-2 found in this study (11%) was similar to that observed in published series of gastric adenOCarcinoma.
[Barrett's esophagus].
TLDR
Barrett's esophagus is a pre-malignant change in esophageal mucosa and the origin of adenocarcinoma and ablation of epithelium in combination with a subsequent long-term antisecretory therapy appears to be a promising treatment.
Quantitative real‐time RT‐PCR detection of breast cancer micrometastasis using a multigene marker panel
TLDR
Evidence is provided that mam, PIP, CK19, mamB, muc1 and CEA can be applied as a panel for detection of metastatic and occult micrometastatic disease.
Real-time reverse transcription-PCR detects KS1/4 mRNA in mediastinal lymph nodes from patients with non-small cell lung cancer.
TLDR
This study investigated the possibility that metastatic disease could be reliably detected in MLNs of NSCLC patients by real-time RT-PCR, and procured by EUS-FNA nine MLNs containing metastaticNSCLC.
Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study.
TLDR
The data obtained from submitted diagnoses as opposed to those from blind review suggest that knowledge of the clinical findings aids in diagnosis, and support the assertion that HGD is strongly associated with invasive carcinoma.
Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation.
TLDR
Both intraobserver and interobserver variation improved overall after the application of a modified grading system developed at a consensus conference but not in separation of BE, IND, and LGD.
...
1
2
3
4
5
...